Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes

Одногормональная и двухгормональная искусственная поджелудочная железа для контроля уровня глюкозы в ночное время у пациентов с сахарным диабетом 1 типа
Ahmad Haidar, Bruce A. Perkins, RÉMI P.R. RABASA-LHORET, Andrej Orszag, Virginie Messier, Laurent Legault, Martin Ladouceur, Leif Erik Lovblom, Rohan Rakheja, Émilie D'Aoust, C. Marcelo Falappa, Tara D. Justice, Holly Tschirhart Menezes, Maryse Dallaire
2015-11-02

continuous glucose monitoringdual-hormone artificial pancreasovernight glucose controlsingle-hormone artificial pancreastype 1 diabetes
CONTEXT: The added benefit of glucagon in artificial pancreas systems for overnight glucose control in type 1 diabetes has not been fully explored. OBJECTIVE: The objective of the study was to compare the efficacy of dual-hormone (insulin and glucagon) artificial pancreas, single-hormone (insulin alone) artificial pancreas, and conventional insulin pump therapy. DESIGN: This study was a three-center, three-arm, open-label, randomized, crossover controlled trial involving three interventions, each applied over a night after a high carbohydrate/high fat meal and a second after exercise to mimic real-life glycemic excursions. SETTING: The study was conducted in a home setting. PATIENTS: Twenty-eight type 1 diabetes participants (21 adults and seven adolescents) participated in the study. INTERVENTIONS: Dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional pump therapy was activated from 9:00 PM to 7:00 AM. MAIN OUTCOME: The main outcome was a proportion of time in target (4-8 mmol/L) by continuous glucose monitoring from 11:00 PM to 7:00 AM. Analysis was by intention to treat. RESULTS: The median (interquartile range) percentage of time-in-target glucose range was 47% (36%-71%) for conventional therapy, higher on both single-hormone (76% [65%-91%], P < .001) and dual-hormone artificial pancreas (81 [68%-93%], P < .001). The median (interquartile range) time spent below 4 mmol/L was 14% (4%-28%) for conventional therapy, lower on both single-hormone (5% [0%-13%], P = .004) and dual-hormone artificial pancreas (1% [0%-8%], P < .001). There were 14 hypoglycemic events on conventional therapy compared with six incidences on the single-hormone artificial pancreas (P = .059) and three incidences on the dual-hormone artificial pancreas (P = .017). None of these outcomes differed significantly between single- and dual-hormone configurations. CONCLUSIONS: Single- and dual-hormone artificial pancreas systems both provided better glucose control than conventional therapy. Although the dual-hormone configuration did not increase overnight time-in-target glucose levels, an effect on lowering hypoglycemia risk cannot be ruled out.
1
Both single-hormone and dual-hormone artificial pancreas systems significantly increased overnight time in the target glucose range compared with conventional pump therapy.
2
Hypoglycemic events were significantly fewer with the dual-hormone system than conventional therapy, while the reduction with single-hormone therapy was not statistically significant.
3
Median time in range increased from 47% with conventional therapy to 76% with single-hormone and 81% with dual-hormone artificial pancreas systems.
4
No measured glucose-control or hypoglycemia outcome differed significantly between single- and dual-hormone artificial pancreas configurations, indicating no demonstrated added overnight benefit from glucagon.
5
Time spent below 4 mmol/L decreased from 14% with conventional therapy to 5% with single-hormone and 1% with dual-hormone systems.

Artificial pancreas systems for overnight glucose control in people with type 1 diabetes

The comparative efficacy of single-hormone (insulin-only) and dual-hormone (insulin-and-glucagon) artificial pancreas systems versus conventional insulin pump therapy in maintaining target glucose levels and preventing hypoglycemia overnight

Publication Details
Publication Date
2015-11-02
Journal
Publisher
ISSN
Cited by
94
Access Type
Author Information
Authors
Ahmad Haidar
Bruce A. Perkins
RÉMI P.R. RABASA-LHORET
Andrej Orszag
Virginie Messier
Laurent Legault
Martin Ladouceur
Leif Erik Lovblom
Rohan Rakheja
Émilie D'Aoust
C. Marcelo Falappa
Tara D. Justice
Holly Tschirhart Menezes
Maryse Dallaire
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%